Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ATIS is on the move! -- Ignore unavailable to you. Want to Upgrade?

To: Marshall Teitelbaum who wrote (1798)	4/27/1999 12:14:00 AM
From: Rick Strange	Read Replies (1) \| Respond to of 2205

It would be nice to know the trial protocols that would answer this question but we won't get as look at those until the panel review. Yes, the Control heal rate and time to heal is much higher, or better, than published results referred to when ATIS had it's panel review or those experienced during the Dermagraft trial. One trend that did emerge during the ATIS trial was that the larger clinics had better results in both Dermagraft and Control than did the small sites, leading one to conclude that the more a clinic treats a condition the better the results...expertise and experience. ORG did point out these results were from their sites that have the most patients enrolled. Another important variable is the question of off-loading or how much a patient is allowed to walk on a limb with an ulcer. Here again; we will have to wait until details of the protocol are available. Maybe their presentation covered some of these details. One other question the release raised, are 200 patients to be treated with Apligraf or is it 200 patients split between Apligraf and Control?